Drug Trial Radar · NCT07204457
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,123
Planned (sponsor's estimate)
Start
Oct 15, 2025
Primary completion
Sep 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- EyeGene Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- BMI Korea
- First posted
- Oct 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine
Conditions
- Meningococcal Infections
Interventions
EG-MCV4Biological
single intramuscular dose on Day 0
MenveoBiological
single intramuscular dose on Day 0
Primary outcomes
What the sponsor says the trial is designed to measure.
- SeroresponseTime frame: 28 days after the vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Catholic University of Eunpyeong St.Mary's Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.